论文部分内容阅读
一种量身定制的药物,可攻击肿瘤细胞的致命弱点,从而缩小或稳定某些较难根治的遗传性癌症患者身上的肿,瘤。此项早期试验成果发表在近期的《新英格兰医学杂志》(NEJM)网络版
A tailored drug that attacks the lethal weakness of tumor cells to reduce or stabilize swollen, neoplastic tumors in some of the more difficult-to-cure hereditary cancer patients. This early trial was published in the recent edition of the New England Journal of Medicine (NEJM) online